TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15733657

Group type: EXPERIMENTAL
Intervention: Standard care (descriptions of pain or undesirable experiences before procedures)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Sympathizing statements after painful events
Number of subjects: 159

Group type: COMPARATOR
Intervention: Attention control (no warnings or sympathizing statements)
Number of subjects: 159
Study: 12971819

Group type: EXPERIMENTAL
Intervention: Experimental group (trained caregivers)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untrained caregivers)
Number of subjects: 16
Study: 11111131

Group type: EXPERIMENTAL
Intervention: Whole-leaf spinach, minced spinach, liquefied spinach, liquefied spinach with dietary fibre (10 g/kg wet weight)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Minced and liquefied spinach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Synthetic carotenoid supplement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 70
Study: 8617114

Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth, metronidazole, tetracycline) for one week
Number of subjects: 112

Group type: COMPARATOR
Intervention: Dual therapy (amoxicillin and omeprazole) for two weeks
Number of subjects: 112
Study: 1411758

Group type: EXPERIMENTAL
Intervention: Isokinetic force/distance curve variation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isoinertial peak force: weight ratios
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Peak force‐‐weight differences
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Heart rates
Number of subjects: 44

Group type: COMPARATOR
Intervention: 50% effort
Number of subjects: 44

Group type: COMPARATOR
Intervention: 100% effort
Number of subjects: 44
Study: 6424494

Group type: EXPERIMENTAL
Intervention: Amino acid support
Number of subjects: 20

Group type: COMPARATOR
Intervention: No amino acid support
Number of subjects: 20
Study: 31952999

Group type: EXPERIMENTAL
Intervention: Nomogram to predict bladder cancer diagnosis
Number of subjects: 4178

Group type: EXPERIMENTAL
Intervention: Training cohort for logistic regression analysis
Number of subjects: 4178

Group type: EXPERIMENTAL
Intervention: Validation cohort for receiver operating curves
Number of subjects: 4178
Study: 29501296

Group type: EXPERIMENTAL
Intervention: Short tympanostomy tubes
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Long Armstrong tubes
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Silicone tympanostomy tubes
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Donaldson tubes
Number of subjects: 378

Group type: COMPARATOR
Intervention: Infections (general)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Tube occlusion, tube extraction, persistent perforation
Number of subjects: 378
Study: 26126133

Group type: EXPERIMENTAL
Intervention: Unsupported sustained lumbar extension posture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Supported dynamic lumbar extension posture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 24076224

Group type: EXPERIMENTAL
Intervention: Test-drink with a favourable tryptophan/LNAA ratio
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Test-drink
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22971493

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: L-CCB
Number of subjects: 50
Study: 20935605

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (20 sessions of treadmill exercise starting one month after surgery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise program (same for both groups)
Number of subjects: 40
Study: 17636512

Group type: EXPERIMENTAL
Intervention: LigaSure haemorrhoidectomy
Number of subjects: 284

Group type: COMPARATOR
Intervention: Diathermy haemorrhoidectomy
Number of subjects: 284
Study: 16085251

Group type: EXPERIMENTAL
Intervention: Lumbar epidural tramadol (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lumbar epidural morphine (4 mg)
Number of subjects: 40
Study: 11967593

Group type: EXPERIMENTAL
Intervention: Tidal volume ventilation strategy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with P(plat) levels exceeding 35 cmH(2)O
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mechanical ventilation with P(plat) lower than 35 cmH(2)O
Number of subjects: 116
Study: 11156038

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9053503

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 10 mg/m2/d
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 20 mg/m2/d
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 25 mg/m2/d
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 30 mg/m2/d
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP)
Number of subjects: 23
Study: 8256303

Group type: EXPERIMENTAL
Intervention: Fluoride rinses with 0.2% neutral sodium fluoride
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 1083
Study: 3940830

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (100 mg) with T.E.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (200 mg) with T.E.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (351 mg) with T.E.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (200 mg) with T.P.D.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 20
Study: 29402513

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) placed in the peri-implant region (n=21)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No augmentation (control group, n=20)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (PRF and control)
Number of subjects: 31
Study: 27737744

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg monthly for 12 months
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 24795254

Group type: EXPERIMENTAL
Intervention: RO5093151 (200 mg twice daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: RO5093151
Number of subjects: 82
Study: 23103618

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil orally
Number of subjects: 49
Study: 20139131

Group type: EXPERIMENTAL
Intervention: PTFE-coated brackets
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uncoated stainless steel brackets
Number of subjects: 13
Study: 18595969

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50000 IU)
Number of subjects: 17116

Group type: COMPARATOR
Intervention: Placebo (oil droplets from gelatinous capsule)
Number of subjects: 17116
Study: 16080445

Group type: EXPERIMENTAL
Intervention: Food supplemented with vitamin C (from kiwi fruits) and vitamin E (in capsules)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain, unsupplemented food
Number of subjects: 60
Study: 12565115

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped when the tourniquet was released (Group 1, n=6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped 15 minutes after tourniquet release (Group 2, n=6)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sufentanil bolus at 0.5 microg kg(‐1) started after tourniquet inflation (Group 3, n=4)
Number of subjects: 16
Study: 10341686

Group type: EXPERIMENTAL
Intervention: High resolution ultrasound (US) analysis of the liver surface
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High resolution ultrasound (US) analysis of the liver surface (including non-diagnostic cases as true-positive and false-positive)
Number of subjects: 100
Study: 7593871

Group type: EXPERIMENTAL
Intervention: Emotional expression group (writing about personal traumatic events)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (writing about control topics)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emotional expression group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 2034482

Group type: COMPARATOR
Intervention: Exchange transfusion only (24%)
Number of subjects: 224
Study: 31580144

Group type: EXPERIMENTAL
Intervention: Baseline data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30346860

Group type: EXPERIMENTAL
Intervention: 80 mg OD at 8:00 AM
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 mg OD at 8:00 PM
Number of subjects: 12

Group type: COMPARATOR
Intervention: 40 mg BID at 8:00 AM and PM
Number of subjects: 12
Study: 27654837

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 31
Study: 26410579

Group type: COMPARATOR
Intervention: Anodal tDCS + sham tsDCS (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS + cathodal tsDCS (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tDCS + cathodal tsDCS (group 3)
Number of subjects: 30
Study: 23357031

Group type: EXPERIMENTAL
Intervention: Ethanol at BAC levels of 0.5g/L and 0.9g/L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drinks and placebo pills
Number of subjects: 20
Study: 20638188

Group type: EXPERIMENTAL
Intervention: Test group scoring system for intracerebral control (IC)
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Validation group scoring system for intracerebral control (IC)
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Test group scoring system for overall survival (OS)
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Validation group scoring system for overall survival (OS)
Number of subjects: 1797
Study: 19756426

Group type: EXPERIMENTAL
Intervention: Misoprostol suppositories
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 100
Study: 17503102

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo-CPAP
Number of subjects: 50
Study: 15467327

Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air breathing (control)
Number of subjects: 10
Study: 11550730

Group type: COMPARATOR
Intervention: Standard contingency management (abstinence group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Contingency designed to increase contact with reinforcers (shaping group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Shaping group
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Escalating‐value vouchers
Number of subjects: 95
Study: 9570192

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: No substitution (control)
Number of subjects: 100
Study: 8072054

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atenolol and Placebo
Number of subjects: 100
Study: 3054626

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg bid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31904760

Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day) with high-fiber wheat bran (30 g fiber/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Whey protein (60 g/day) with low-fiber refined wheat (10 g fiber/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Maltodextrin with high-fiber wheat bran (30 g fiber/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Maltodextrin with low-fiber refined wheat (10 g fiber/day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Whey protein (60 g/day)
Number of subjects: 65
Study: 28474319

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 150
Study: 25117433

Group type: EXPERIMENTAL
Intervention: Ball-carry group (BC; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-ball-carry group (NBC; n = 12)
Number of subjects: 24
Study: 23523423

Group type: EXPERIMENTAL
Intervention: 3× loupe magnified inguinal varicocelectomy (Group A & B1)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Conservative management (Group B2)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 3× loupe magnified inguinal varicocelectomy (Group B1)
Number of subjects: 173
Study: 21443316

Group type: EXPERIMENTAL
Intervention: EC-enhancing intervention (15-hour group format intervention with a 4-week e-mail follow-up)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 18205902

Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 68

Group type: COMPARATOR
Intervention: Paper
Number of subjects: 68
Study: 16989679

Group type: EXPERIMENTAL
Intervention: Telemedicine interventions (specifics not provided)
Number of subjects: 0
Study: 12706935

Group type: EXPERIMENTAL
Intervention: Bosentan (125 or 250 mg twice daily)
Number of subjects: 85
Study: 11022397

Group type: COMPARATOR
Intervention: Tropicamide (20 microL, 0.01%) administered to one eye and placebo to the other.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tropicamide (20 microL, 0.01%) followed by pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg, intravenously) administered in separate sessions.
Number of subjects: 19
Study: 8612392

Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1596225

Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 1)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Silicone oil (group 1)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 2)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Silicone oil (group 2)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas (group 1, follow-up ≥ 18 months)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Silicone oil (group 1, follow-up ≥ 18 months)
Number of subjects: 265
Study: 6692384

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate (60 mg, 3 times/day for 30 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 38
Study: 29122709

Group type: EXPERIMENTAL
Intervention: Letrozole (10mg daily for 3 days) followed by vaginal misoprostol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 78
Study: 27113048

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metoprolol succinate (100 mg per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23707383

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), n=50
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting List (WL) control, n=48
Number of subjects: 98
Study: 21987516

Group type: EXPERIMENTAL
Intervention: Emotional abuse with physical and/or sexual abuse
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: Emotional abuse alone
Number of subjects: 1293

Group type: COMPARATOR
Intervention: No abuse
Number of subjects: 1293
Study: 20886797

Group type: EXPERIMENTAL
Intervention: Acupuncture articles
Number of subjects: 583
Study: 18545180

Group type: EXPERIMENTAL
Intervention: 8-second resting interval
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 14-second resting interval
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 17-second resting interval
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20-second resting interval
Number of subjects: 10
Study: 15877550

Group type: EXPERIMENTAL
Intervention: Exercisers (reporting > or = 1,000 kcal/wk of exercise activity)
Number of subjects: 3075

Group type: COMPARATOR
Intervention: Inactive persons (reporting < 1,000 kcal/wk of exercise activity and < 2,719 kcal/wk of total physical activity)
Number of subjects: 3075

Group type: EXPERIMENTAL
Intervention: Lifestyle active (reporting < 1,000 kcal/wk of exercise activity and > or = 2,719 kcal/wk of total physical activity)
Number of subjects: 3075
Study: 12821232

Group type: EXPERIMENTAL
Intervention: Folic acid 0.5 mg/day
Number of subjects: 593

Group type: COMPARATOR
Intervention: Control
Number of subjects: 593
Study: 10826403

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg daily)
Number of subjects: 24
Study: 8652214

Group type: EXPERIMENTAL
Intervention: 6% hypertonic saline (HS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% isotonic saline (IS)
Number of subjects: 10
Study: 1509383

Group type: EXPERIMENTAL
Intervention: Gastrozepin (22 persons)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ranisan (23 persons)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (15 subjects)
Number of subjects: 45
Study: 6382981

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 73

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 73
Study: 30570309

Group type: EXPERIMENTAL
Intervention: CBTsa (Cognitive Behavioral Therapy for social activation)
Number of subjects: 99

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CBTsa
Number of subjects: 99

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 99
Study: 27269367

Group type: EXPERIMENTAL
Intervention: Good adherence to the Mediterranean diet
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Higher intake of sweets, sugar‐sweetened beverages, and fast foods
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Vegetable intake
Number of subjects: 1643

Group type: COMPARATOR
Intervention: KIDMED score
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Blood pressure
Number of subjects: 1643
Study: 26016955

Group type: EXPERIMENTAL
Intervention: Grief intervention treatment group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual standard care control group
Number of subjects: 40
Study: 23444920

Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21276961

Group type: EXPERIMENTAL
Intervention: Extended-release niacin monotherapy (48 weeks; n=31)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Matched placebo (n=23)
Number of subjects: 54
Study: 19968385

Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 254
Study: 16520433

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 12743670

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quinine hydrochloride 250 mg with four other CYP probe drugs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg with ketoconazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride 250 mg with fluvoxamine
Number of subjects: 24
Study: 11368286

Group type: EXPERIMENTAL
Intervention: IV levosimendan
Number of subjects: 0
Study: 9337806

Group type: EXPERIMENTAL
Intervention: Periodic health exam including blood pressure testing, cholesterol screening, and baseline ECG
Number of subjects: 0
Study: 7524040

Group type: EXPERIMENTAL
Intervention: HOME Inventory (IT-HOME) at 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOME Inventory (EC-HOME) at 36 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of the home environment (measured by HOME Inventory)
Number of subjects: 0
Study: 3302868

Group type: COMPARATOR
Intervention: Cefotaxime (C)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cefazolin plus Tobramycin (C + T)
Number of subjects: 47
Study: 29338584

Group type: EXPERIMENTAL
Intervention: βHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: plain water (3.8 mL kg body mass‐1) (CON)
Number of subjects: 19
Study: 26913621

Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-directed physical activity education (EC)
Number of subjects: 64
Study: 25567121

Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training coupled with falls prevention education
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Movement strategy training combined with falls prevention education
Number of subjects: 210

Group type: COMPARATOR
Intervention: Life-skills information (control)
Number of subjects: 210
Study: 24162833

Group type: COMPARATOR
Intervention: Direct cardioversion (group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Further ablation of subsequent atrial tachycardias to sinus rhythm (group B)
Number of subjects: 110
Study: 21368750

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg b.i.d. for 9 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: amiloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: urinary α-ENaC
Number of subjects: 12

Group type: COMPARATOR
Intervention: furosemide
Number of subjects: 12
Study: 19451669

Group type: EXPERIMENTAL
Intervention: Tailored advice
Number of subjects: 302

Group type: COMPARATOR
Intervention: Generic advice
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Tailored advice with action plan
Number of subjects: 302
Study: 16490809

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg coadministered with CyA (75-150 mg twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg with CyA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study: 14508021

Group type: EXPERIMENTAL
Intervention: Placebo group (received information about pain relieving injection)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nocebo group (received information about pain increasing injection)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Natural History group (received no information and no injection)
Number of subjects: 59